Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma, listed on NASDAQ as TBPH, will participate in the Bank of America 2021 Healthcare Conference on May 13 at 2:45 p.m. ET. CEO Rick E Winningham will present during the event, which can be accessed via a webcast on the company's website. The presentation will focus on the company's mission to develop organ-selective medicines aimed at improving patient outcomes in serious illnesses, particularly in inflammation and immunology.
- None.
- None.
DUBLIN, May 6, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in an investor event as follows:
- Rick E Winningham (Chief Executive Officer) will be presenting at the Bank of America 2021 Healthcare Conference on Thursday, May 13 at 2:45 p.m. ET (11:45 a.m. PT/7:45 p.m. IST)
Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for at least 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.
In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant patient needs.
We have an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact Information:
Gail Cohen
Corporate Communications
917-214-6603
investor.relations@theravance.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301285188.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma present at the Bank of America 2021 Healthcare Conference?
Who is presenting on behalf of Theravance Biopharma at the conference?
How can I access the Theravance Biopharma conference presentation?
What is the focus of Theravance Biopharma's research?
What is the stock symbol for Theravance Biopharma?
